Itragreat SB 130mg Capsule contains itraconazole, a broad-spectrum triazole antifungal agent used for the treatment of various systemic and superficial fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is indicated for the management of infections such as aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and other dermatophytic infections. Itragreat SB 130mg Capsule is typically administered orally, with dosing regimens tailored according to the type and severity of the infection, as well as patient-specific factors. It is important to adhere to the prescribed duration of therapy to ensure complete eradication of the fungal pathogen and to prevent resistance development. Common side effects may include gastrointestinal disturbances, headache, and rash, while more serious adverse reactions such as hepatotoxicity and cardiac effects require close monitoring. Itraconazole has potential drug interactions due to its effect on cytochrome P450 enzymes; therefore, concomitant use with certain medications should be approached with caution. This product should be used under medical supervision, with periodic assessment of liver function and clinical response to optimize therapeutic outcomes.